Pablo Ljaskowsky joined Xeltis as Chief Financial Officer. Mr. Ljaskowsky was recently a partner at KPMG’s Transaction Services group, advising clients on mergers, acquisitions and divestitures in various industries.

Mr. Ljaskowsky commented: “Xeltis is one of the most promising companies I have come across in the recent years. The potential to disrupt the treatment of large cardiovascular diseases, the ground-breaking Nobel-prize winning technology and the wide scope of applications make Xeltis a truly unique company. The prospect of participating to the development of products that could save children’s lifes is also incredibly gratifying. Finally, I am delighted to join such a talented and energetic team.”